During an event with Massachusetts Gov. Charlie Baker in June, Abiomed announced a major expansion of its U.S. headquarters in Danvers, Massachusetts, and the creation of approximately 100 new, local jobs.

Mercom Capital Group llc, a global communications and research firm, released its report on funding and mergers and acquisitions (M&A) activity for the Healthcare Information Technology (IT)/Digital Health sector for the second quarter of 2015. The comprehensive report covers deals of all sizes across the globe.

Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of their proposed merger.

The Society for Heart Attack Prevention and Eradication (SHAPE) submitted a letter to the U.S. Preventive Services Task Force (USPSTF) strongly supporting the use of coronary artery calcium to assess an individual's risk of heart attack.

C.R. Bard, LEVANT 2 results, Lutonix 035 DCB, drug coated balloon, PTA

C.R. Bard Inc. announced the publication of results from the LEVANT 2 study in the June 24, 2015, online issue of The New England Journal of Medicine. Results from LEVANT 2 demonstrated superior primary patency for the Lutonix 035 drug coated balloon percutaneous transluminal angioplasty (PTA) catheter over standard PTA, as well as safety consistent with standard PTA balloons. The Lutonix 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.

Masimo announced the CE Mark and full market release of MightySat Rx fingertip pulse oximeter for clinical use in CE countries. The device uses Masimo’s SET Measure-Through Motion and Low Perfusion pulse oximetry.

Biosense Webster Inc. announced the launch of the Confidense Module, an innovative technology that streamlines the creation of real-time 3-D maps of a patient’s cardiac structures during catheter ablation procedures. Utilizing an advanced, proprietary algorithm, the module enhances the process for validating information, or “points,” acquired during multi-electrode mapping, enabling electrophysiologists to focus their time and expertise on the most relevant data during the mapping process.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now